Libero Pharma
Developer of transdermal patch formulations delivering naltrexone (an opioid receptor antagonist) aimed at psychiatric, CNS and inflammatory indications. The company focuses on formulation development to enable sustained, non-invasive delivery, leverages existing clinical data to accelerate regulatory pathways, and has received external grant funding to support development.
Industries
Nr. of Employees
small (1-50)
Libero Pharma
Edinburgh, Edinburgh, City of, United Kingdom, Europe
Patents
Products
Transdermal patches delivering naltrexone for multiple indications
Pipeline of transdermal patch products designed to deliver sustained levels of naltrexone for indications including opioid use disorder, alcohol use disorder, fibromyalgia and Crohn's disease.
Libero Pharma Transdermal Naltrexone Patch
A lead transdermal treatment using sustained-release naltrexone formulations to benefit patients with chronic conditions that respond to opioid receptor antagonism.
Transdermal patches delivering naltrexone for multiple indications
Pipeline of transdermal patch products designed to deliver sustained levels of naltrexone for indications including opioid use disorder, alcohol use disorder, fibromyalgia and Crohn's disease.
Libero Pharma Transdermal Naltrexone Patch
A lead transdermal treatment using sustained-release naltrexone formulations to benefit patients with chronic conditions that respond to opioid receptor antagonism.
Expertise Areas
- Transdermal drug delivery
- Clinical development for CNS and psychiatric conditions
- Formulation development and IP strategy
- Regulatory strategy and expedited pathways
Key Technologies
- Transdermal patch formulations
- Sustained-release transdermal delivery
- Formulation patenting
- Clinical protocol development for CNS indications
News & Updates
Received a multi-year development grant from the US National Institute on Drug Abuse (NIDA); cited as the largest NIDA grant issued to an ex-US entity in 2022 to support development of the lead medicine.
Received a multi-year development grant from the US National Institute on Drug Abuse (NIDA); cited as the largest NIDA grant issued to an ex-US entity in 2022 to support development of the lead medicine.